Skip to content

HidraWear Study for Hidradenitis Suppurativa Wounds

A Study to Evaluate the HS Specific Wound Dressing HidraWear AX in the Home Setting

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04449354
Enrollment
16
Registered
2020-06-26
Start date
2019-10-30
Completion date
2020-10-03
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis, Hidradenitis Suppurativa

Brief summary

The product, HidraWear AX (www.hidrawear.com) is and adhesive free wound dressing system for the every day home care of Hidradenitis Suppurativa (HS), a debilitating disease of the skin for which there are limited wound dressing products. This is a study to assess the use HidraWear Ax vs current product and method of use, and to determine the impact on patients' quality of life.

Detailed description

The objective is to evaluate the ease of use of Hidrawear AX compared to the subject's existing product use in 23 subjects with HS (Hidradenitis Suppurativa). Secondary objectives are to evaluate if Hidrawear AX: * Is comfortable * Improves quality of life * Faster to use than the subject's existing product * Reduces dressing related pain * Secure dressing retention This pilot study will evaluate usability - the safety, efficacy and performance of HidraWear AX in the home setting. Quality of life, ease of use and comfort of Hidrawear AX will be assessed. The clinical effect of the wound pad will not be assessed.

Interventions

DEVICEHidraWear Ax

An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.

Sponsors

HidraMed Solutions Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form in English. 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Female, aged \>18 4. Diagnosed with Hidradenitis Suppurativa 5. Hidradenitis Suppurativa affecting the axilla 6. Exuding lesion that requires wound dressings

Exclusion criteria

* 1\. Recent surgery \<3 months in axilla 2. Psoriasis, Dermatitis or skin conditions/rash other than Hidradenitis Suppurativa on or near affected area 3. Pregnancy or lactation 4. Known allergic reactions to components of Hidrawear AX

Design outcomes

Primary

MeasureTime frameDescription
Ease of Use Day 21 vs Day 03 weeks10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. self reported . A score of 0 means the product is very easy to use, and a score of 10 means the product is very difficult to use. A lower score represents a better outcome.

Secondary

MeasureTime frameDescription
Visual Pain Analogue Scale Day 21 vs Day 03 weeksPatient reported pain, 10 point scale, high score indicates pain. 10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. self reported . A score of 0 means the patient experiences no pain, and a score of 10 means the patient experiences extreme pain. A lower score represents a better outcome.
Time Taken to Dress Wounds3 weeks10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the product is very quick to use, and a score of 10 means the product is very time consuming to use. A lower score represents a better outcome.
Change in Quality of Life (QoL) Measured Using the Dermatology Life Quality Index (DLQI)3 weeksThe Dermatology Life Quality Index (DLQI) is a ten-item questionnaire designed to measure the impact of skin diseases on patients' quality of life, focusing on symptoms, daily activities, leisure, work or school, personal relationships, and treatment. It provides a quick and quantifiable assessment, with scores ranging from 0 (no impact) to 30 (extremely large impact), facilitating the evaluation of disease severity and treatment efficacy. A lower score represents a better outcome.
Patient Comfort3 weeks10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the product is very comfortable to use and wear, and a score of 10 means the product is very uncomfortable to use and wear. A lower score represents a better outcome.
Confidence in Dressing Product (Secure Retention, Leak Reduction)3 weeks10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the patient is confident in the products ability to remain in place and contain exudate, and a score of 10 indicates low confidence in products ability to remain in place or contain exudate. A lower score represents a better outcome.
Body Image Visual Analogue Scale3 weeks10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the patient feels confident about their body image, and a score of 10 means the patient does not feel confident at all about their body image. A lower score represents a better outcome.

Countries

Ireland

Participant flow

Participants by arm

ArmCount
HidraWear AX
HidraWear AX Garment HidraWear Ax: An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated panel is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. Participants used HidraWear AX for 21 days
16
Total16

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicHidraWear AX
Age, Categorical
<=18 years
16 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Ireland
16 Participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 0
other
Total, other adverse events
0 / 15
serious
Total, serious adverse events
0 / 15

Outcome results

Primary

Ease of Use Day 21 vs Day 0

10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. self reported . A score of 0 means the product is very easy to use, and a score of 10 means the product is very difficult to use. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXEase of Use Day 21 vs Day 0Day 06.47 score on a scaleStandard Deviation 2.75
HidraWear AXEase of Use Day 21 vs Day 0Day 210.6 score on a scaleStandard Deviation 1.59
Secondary

Body Image Visual Analogue Scale

10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the patient feels confident about their body image, and a score of 10 means the patient does not feel confident at all about their body image. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXBody Image Visual Analogue ScaleDay 213.8 score on a scaleStandard Deviation 2.18
HidraWear AXBody Image Visual Analogue ScaleDay 08.53 score on a scaleStandard Deviation 1.92
Secondary

Change in Quality of Life (QoL) Measured Using the Dermatology Life Quality Index (DLQI)

The Dermatology Life Quality Index (DLQI) is a ten-item questionnaire designed to measure the impact of skin diseases on patients' quality of life, focusing on symptoms, daily activities, leisure, work or school, personal relationships, and treatment. It provides a quick and quantifiable assessment, with scores ranging from 0 (no impact) to 30 (extremely large impact), facilitating the evaluation of disease severity and treatment efficacy. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXChange in Quality of Life (QoL) Measured Using the Dermatology Life Quality Index (DLQI)Day 019.3 score in the DLQI QuestionnaireStandard Deviation 5.73
HidraWear AXChange in Quality of Life (QoL) Measured Using the Dermatology Life Quality Index (DLQI)Day 214.53 score in the DLQI QuestionnaireStandard Deviation 3.93
Secondary

Confidence in Dressing Product (Secure Retention, Leak Reduction)

10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the patient is confident in the products ability to remain in place and contain exudate, and a score of 10 indicates low confidence in products ability to remain in place or contain exudate. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXConfidence in Dressing Product (Secure Retention, Leak Reduction)Day 08.4 score on a scaleStandard Deviation 2.53
HidraWear AXConfidence in Dressing Product (Secure Retention, Leak Reduction)Day 211.2 score on a scaleStandard Deviation 1.82
Secondary

Patient Comfort

10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the product is very comfortable to use and wear, and a score of 10 means the product is very uncomfortable to use and wear. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXPatient ComfortDay 08.13 score on a scaleStandard Deviation 1.92
HidraWear AXPatient ComfortDay 211 score on a scaleStandard Deviation 1.25
Secondary

Time Taken to Dress Wounds

10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. Self reported . A score of 0 means the product is very quick to use, and a score of 10 means the product is very time consuming to use. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXTime Taken to Dress WoundsDay 06.93 score on a scaleStandard Deviation 2.46
HidraWear AXTime Taken to Dress WoundsDay 210.67 score on a scaleStandard Deviation 1.4
Secondary

Visual Pain Analogue Scale Day 21 vs Day 0

Patient reported pain, 10 point scale, high score indicates pain. 10 point visual analogue scale with a maximum score of 10 and a minimum score of 0. self reported . A score of 0 means the patient experiences no pain, and a score of 10 means the patient experiences extreme pain. A lower score represents a better outcome.

Time frame: 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
HidraWear AXVisual Pain Analogue Scale Day 21 vs Day 0Day 05.53 score on a scaleStandard Deviation 2.5
HidraWear AXVisual Pain Analogue Scale Day 21 vs Day 0Day 210.80 score on a scaleStandard Deviation 1.67

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026